Showing 451-460 of 5000 results for "".
Make Your Mark: Formulate a Product Line
https://practicaldermatology.com/topics/practice-management/make-your-mark-formulate-a-product-line/20023/Dispensing skincare offers benefits to your practice and your patients. Joel Schlessinger, MD discusses his journey with his son to developing their own product formulation and offers insights and encourages colleagues to use their unique talents to do the same.Viora Marketing Summary 2010
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/viora-marketing-summary-2010-/19450/Various Doctors give their opinions on the benefits of using Viora for Cellulite Treatment, Circumferential Reduction and Skin Tightening for the Face & Body.Staff Training and Manuals
https://practicaldermatology.com/topics/practice-management/staff-training-and-manuals/19494/The Secret Sauce for Managing AD
https://practicaldermatology.com/conferences/scale-2023/the-secret-sauce-for-managing-ad/20190/James Del Rosso, DO, discusses new and upcoming therapies for atopic dermatitis including monoclonal antibodies and JAK inhibitors.Making Connections: Success in Your First Five Years
https://practicaldermatology.com/topics/practice-management/webinar-making-connections-success-in-your-first-five-years/19819/Experts share practical guidance to help dermatologists chart a course for success. Topics range from getting involved in clinical trials to finding opportunities for leadership. Learn how to gain confidence prescribing systemic agents, and explore opportunities in medical dermatology.DermwireTV — Valeant Ups Allergan Bid, Nestle Buys Injectables, and Allergan Makes Its Case
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-valeant-ups-allergan-bid-nestle-buys-injectables-and-allergan-makes-its-case/19128/BREAKING NEWS: Valeant has increased its offer for Allergan to $72 per share. Read more. Valeant sells the rights to its aesthetic injectables to Nestle, while Allergan touts physician support and challenges Valeant's business model. In this week's edition of DermWireTV, learn about Valeant's latesCrisis Management: Office Operations, Part 1
https://practicaldermatology.com/topics/practice-management/crisis-management-office-operations-part-1/18181/How are primarily cosmetic dermatology practices dealing with shutdowns and preparing for the future? Host Neal Bhatia, MD discusses with Deirdre Hooper, MD, Ashish Bhatia, MD, Kevin Pinski, MD, and Nancy Samolitis, MD.DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourAn Updated, Holistic Approach to Managing Hyperpigmentation
https://practicaldermatology.com/topics/pigmentary-disorders/an-updated-holistic-approach-to-managing-hyperpigmentation/20102/As an early adopter of Cyspera, Suneel Chilukuri, MD has witnessed the evolution of the topical formulation. Cyspera Intensive System provides a three-step holistic approach to skincare that supports healthier, brighter skin within about four to six weeks.A Matter of Scales
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/a-matter-of-scales/19917/The "classic" descriptions of skin diseases and the scales used to assess disease severity often are based on white skin. But skin diseases can appear differently across skin types. The panelists discuss the need for updated tools, including the need to rethink skin type scales.